5Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3 ) in the treatment of acute myelogenous leukemia: As2O3 induces NB4 cells apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood, 1996,88:1052-1061.
2[1]Shen Z X, Chen G Q, Ni J H, et al. Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia: II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 1997, 89: 3354-3360.
3[2]Chen Z, Wang Z Y, Chen S J. Acute promyelocytic leukemia:cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther, 1997, 76:141-149.
4[3]Niu C, Yan H, Yu T, et al. Studies of Treatment of Acute Pro-myelocytic Leukemia with Arsenic Trioxide: remission induction, follow-up, and molecular monitoring in 11 newly-diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 1999, 94:3315-3324.
4Tallman MS,Andersen JW,Schiffer CA,et al.Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome[J].Blood,2001,95:90-95.
5Melnick A,Licht JD.Deconstructing a disease:RARalpha,its fusion partners,and their roles in the pathogenesis of acute promyelocytic leukemia[J].Blood,1999,93:3167-3215.
